The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is a chain of interactions between proteins in a cell.
The JAK-STAT signaling pathway transmits information from extracellular chemical signals to the nucleus resulting in DNA transcription and expression of genes involved in immunity, proliferation, differentiation, apoptosis and oncogenesis. This pathway plays a prominent role in mediating signal transduction for many cytokines.
There are three key parts of JAK-STAT signaling pathway: Janus kinases (JAKs), Signal Transducer and Activator of Transcription proteins (STATs), and receptors (which bind the chemical signals). In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors.
Following the binding of cytokines to their cognate receptor, STATs are activated by members of the JAK family of tyrosine kinases. Once activated, they dimerize and translocate to the nucleus and modulate the expression of target genes.
In addition to the activation of STATs, JAKs mediate the recruitment of other molecules such as the MAP kinases, PI3 kinase etc. These molecules process downstream signals via the Ras-Raf-MAP kinase and PI3 kinase pathways which results in the activation of additional transcription factors.
Dysregulation of JAK-STAT signaling is associated with various immune disorders. Accumulating evidence has discovered that STAT3 SNPs is associated with Crohn’s disease, psoriasis and ankylosing spondylitis, STAT4 SNPs is associated with rheumatoid arthritis, Crohn’s disease, systemic lupus erythematosus and Sjogren’s syndrome, and STAT6 SNPs is associated with asthma.
Additionally, given the researches implicating JAK-STAT in autoimmune disease and malignancy, it is not surprising that this pathway has become an attractive target for pharmaceuticals. Ruxolitinib, a JAK1 and JAK2 inhibitor with efficacy for the treatment of polycythemia vera and myelofibrosis, was the first FDA approved JAK inhibitor, or Jakinib.
|IFNA2||IFNA2 Antibody||IFNA2 Protein||IFNA2 cDNA||IFNA2 ELISA Kit|
|IFNA21||IFNA21 Antibody||IFNA21 Protein||IFNA21 cDNA||IFNA21 ELISA Kit|
|IFNA4||IFNA4 Antibody||IFNA4 Protein||IFNA4 cDNA||IFNA4 ELISA Kit|
|IFNA5||IFNA5 Antibody||IFNA5 Protein||IFNA5 cDNA||IFNA5 ELISA Kit|
|IFNA6||IFNA6 Antibody||IFNA6 Protein||IFNA6 cDNA||IFNA6 ELISA Kit|
|IFNA7||IFNA7 Antibody||IFNA7 Protein||IFNA7 cDNA||IFNA7 ELISA Kit|
|IFNAR1||IFNAR1 Antibody||IFNAR1 Protein||IFNAR1 cDNA||IFNAR1 ELISA Kit|
|IFNAR2||IFNAR2 Antibody||IFNAR2 Protein||IFNAR2 cDNA||IFNAR2 ELISA Kit|
|IFNB1||IFNB1 Antibody||IFNB1 Protein||IFNB1 cDNA||IFNB1 ELISA Kit|
|IFNE||IFNE Antibody||IFNE Protein||IFNE cDNA||IFNE ELISA Kit|
|IFNG||IFNG Antibody||IFNG Protein||IFNG cDNA||IFNG ELISA Kit|
|IFNGR1||IFNGR1 Antibody||IFNGR1 Protein||IFNGR1 cDNA||IFNGR1 ELISA Kit|
|IFNGR2||IFNGR2 Antibody||IFNGR2 Protein||IFNGR2 cDNA||IFNGR2 ELISA Kit|
|IFNK||IFNK Antibody||IFNK Protein||IFNK cDNA||IFNK ELISA Kit|
|IFNL1||IFNL1 Antibody||IFNL1 Protein||IFNL1 cDNA||IFNL1 ELISA Kit|
|IFNL2||IFNL2 Antibody||IFNL2 Protein||IFNL2 cDNA||IFNL2 ELISA Kit|
|IFNL3||IFNL3 Antibody||IFNL3 Protein||IFNL3 cDNA||IFNL3 ELISA Kit|
|IFNLR1||IFNLR1 Antibody||IFNLR1 Protein||IFNLR1 cDNA||IFNLR1 ELISA Kit|
|IFNW1||IFNW1 Antibody||IFNW1 Protein||IFNW1 cDNA||IFNW1 ELISA Kit|
|IL10||IL10 Antibody||IL10 Protein||IL10 cDNA||IL10 ELISA Kit|